On p. 912 of the September issue, Cambridge Drug Discovery (Cambridge, UK) was incorrectly cited as the acquisition target of Millennium Pharmaceuticals (Cambridge, MA). Cambridge Discovery Chemistry (Cambridge, UK) was the company that was acquired. In the same issue, on p. 940, the caption for Figure 2 should have read “Negative questions are reverse scored in this graph so that in each case more positive or pro-biotechnology responses are toward the left” rather than “toward the right.” Also, on p. 1013, the accompanying images for Nonlinear Dynamics' Phoretix Array2 and BioDiscovery's AutoGene software were reversed. On p. 1025 of the October issue, Alan Dove (not Natalie DeWitt) authored “A snare for the weak.”
Additional information
The online version of the original article can be found at 10.1038/79324
The online version of the original article can be found at 10.1038/79412
The online version of the original article can be found at 10.1038/79289
Rights and permissions
About this article
Cite this article
Erratum. Nat Biotechnol 18, 1125 (2000). https://doi.org/10.1038/81031
Issue Date:
DOI: https://doi.org/10.1038/81031
